anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AMJEVITA is intended for use under the guidance and supervision of a physician. A patient may self-inject AMJEVITA or a caregiver may inject AMJEVITA using either the AMJEVITA prefilled SureClick autoinjector or prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

AMJEVITA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap or cover while allowing it to reach room temperature. Carefully inspect the solution in the AMJEVITA prefilled SureClick autoinjector or prefilled syringe for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. AMJEVITA does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe. 

Instruct patients using the AMJEVITA prefilled SureClick autoinjector or prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
BACKGROUND: The Systemic Immune-Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI) are novel composite inflammatory markers. Previous studies suggest that obesity in individuals correlates with persistently low levels of chronic inflammation. This study aims to explore the association between SII and SIRI and Body Mass Index (BMI) among children and adolescents.
METHODS: A cross-sectional survey was conducted using the National Health and Nutrition Examination Survey (NHANES) dataset from 2 consecutive cycles from 2017-2020. Multivariate linear regression models were employed to examine the linear relationships between BMI and SII and SIRI. Non-linear associations were explored using smooth curve fitting and threshold effect analysis.
RESULTS: A total of 2980 children and adolescents aged 6-19 years were included in this population-based study. In the population description of body mass index categories, we found progressively higher levels of SII and SIRI, notably peaking among obese children (SII mean ± SD: 528.83 ± 285.46; SIRI mean ± SD: 1.12 ± 0.79). Weighted multivariate linear regression confirmed a significant positive association between BMI and both inflammatory indices (P < 0.0001). Subgroup analyses revealed consistent correlations across gender divisions and highlighted a non-linear relationship between BMI and SII.
CONCLUSIONS: SII and SIRI are positively associated with BMI in children and adolescents, indicating their potential as markers for assessing systemic inflammation in pediatric obesity. Further large-scale prospective studies are required to substantiate these findings.
An 18-month open-label pilot study would be conducted at three university referral centres in Tehran, Iran. All patients are at least 50 years old, met the criteria for AD according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and failed treatment with the cholinesterase inhibitor Rivastigmine for any reason. A baseline medical history will be taken and physical examination will be performed for all participants, and any comorbidities and concomitant therapies would be noted. Patients with controlled concomitant diseases, such as hypertension and diabetes, will be allowed to enter the study. Mini-Mental State Examination (MMSE)10 and Alzheimer disease assessment scale-cognitive sub scale11 (ADAS-cog) will be used to measure treatment efficacy. MLC601 will be prescribed as one capsule three times daily without an escalation dose. Safety and tolerability evaluations included physical examinations, electrocardiography, vital sign monitoring and laboratory testing weekly for the first 8 weeks and every 4 weeks thereafter. The MMSE and ADAS-cog will be recorded at each efficacy follow-up visit.
The present disclosure relates to a biologically active biomatrix composition. In one embodiment, the biomatrix composition is derived from human amnions. The biomatrix is termed HuBiogelTM. The composition of HuBiogelTM closely mimics naturally occurring basement membrane compositions and is capable of supporting a wide variety of cell types in vitro and in vivo. The HuBiogelTM biomatrix disclosed comprises, in one embodiment, laminin, collagen I, and collagen IV, and may further comprise any combination of the following: entactin, tenascin, fibronectin and proteoglycans. The biomatrix composition is essentially free of endogenous growth factors and proteolytic enzymes. Also described are two- and three-dimensional culture systems and physiological/pathological model systems utilizing the HuBiogelTM compositions. The HuBiogelTM compositions may be modified to contain desired growth stimulants, such as growth factors, polypeptides and organic mall molecules, and may also contain growth inhibitory agents and/or therapeutic agents.
Of the strategies considered to limit the discomfort of corticosteroid injection, one is to inject without lidocaine to reduce the total volume and avoid acidity. In a Bayesian trial, adults receiving corticosteroid injections were randomized to receive 0.5 mL of triamcinolone with or without 0.5 mL of lidocaine. Serial analysis was performed until a 95% probability of presence or absence of a 1.0-point difference in pain intensity on the 0-10 Numerical Rating Scale was reached. Injections with lidocaine were associated with a median of 2.4-point lower pain intensity during injection with a 95% probability of at least a 1-point reduction. The 95% probability was confirmed in 90% of the repeated analysis (36/40). Lidocaine is associated with lower immediate pain intensity during corticosteroid injection for hand and wrist conditions.Level of evidence: I.
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to pharmaceutical compositions meant for treating diseases for which there is excess mucus in the respiratory channel, such as cytofibrosis and chronic obstructive pulmonary disease. Proposed is a composition which promotes excretion of mucus, containing one or several glycosaminoglycans and amino acid, which is a dry mixture lung inhalation. Proposed is use of a pharmaceutical composition, which promotes excretion of mucus, in therapy. A method of treating lung disease is proposed. A method of producing a composition, involving spray drying of one or more glycosaminoglycans, is proposed. A method of producing a composition, involving jet grinding of one or more glycosaminoglycans, is proposed. ^ EFFECT: possibility of effective dosing mucoactive agents in form of dry powders. ^ 32 cl, 3 tbl, 4 dwg
Purpose In order to develop knowledge and skills for a certain period of time, training is required for the BLS intervention to be performed in cases of cardiac arrest. It is important to provide BLS training for teachers who can reach a large part of the society. Therefore, it would be beneficial to train pre-service teachers on this subject during their education. BLS studies for teachers in the literature are generally limited to descriptive or one-time theoretical face-to-face trainings. This research is planned to evaluate the effects of digital stories and face-to-face applied basic life support training on the knowledge and skill levels of teacher candidates.

Method The universe of the research will consist of 711 pre-service teachers studying in the 3rd grade of Trabzon University teaching departments. The sample will consist of a total of 76 teacher candidates selected by power analysis. The sample group determined by the stratified sampling method from the departments of the education faculty will be selected according to the simple random sampling method and distributed to the groups as 38 digital storytelling and 38 face-to-face applied training groups. In this pretest-posttest experimental study, data will be collected by using the student descriptive characteristics form, Basic Life Support Information Form and Basic Life Support Skills Evaluation Form in the pre-test. After the pre-test, BLS training will be carried out with digital storytelling for one group and face-to-face applied to the other group. The initiatives of both groups will last two months according to the program. After the training, post-test applications will be given to both groups. A permanence test will be given to both groups 1 month after the post-test.
The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or in water. The tablets include silicified microsrystalline cellulose. They are especially suitable for antibiotics. These tablets are also suitable for use in pediatric patients in the age above 3 years. For pediatric patients under 3 years the same tablets can be used as dispersible tablets. Rapidly disintegrating tablets which contain amoxicillin and clavulanic acid are also described.
PROBLEM TO BE SOLVED: To produce a mixed inorganic filler with a high density in a short time by a simple process by previously mixing two or more kinds of inorganic substances with different particle sizes, pulverizing the mixture with high speed air flow, and then sorting the pulverized mixture in the case of producing the mixed inorganic filler from two or more kinds of inorganic substances with different particle sizes. SOLUTION: Common fillers such as silica, alumina, zirconia, aluminum hydroxide, etc., are among the inorganic particles to be used. Two or more kinds of such inorganic particles are use. In this case, one of the particle preferably has 0.01-1μm particle size. At the time of mixing these inorganic particles, the particles are previously mixed by using a mixing apparatus in a dry and batch manner and the pre-mixed coarse powder mixture is pulverized by high speed air flow. The apparatus to be used for mixing and pulverizing the powder is preferably a jet mill. After that, in the sorting process, the sorting is carried out by using a centrifugal mixing type sorting apparatus, especially mesh type sorting apparatus, and consequently, a uniform mixture is produced.
In order to evaluating the efficacy, safety and immune mechanism of Sanjin tablets for the treatment of acute simple lower urinary tract infection and its influence on recurrence rate and through research data to guide clinical, improving the rational use of drugs, especially the rational application of antibiotics. In this study, a randomized, double blind, parallel control of positive drugs, multi-center clinical study will be established. According to the relevant regulations of the CFDA, 252 cases need to be registered at least. These cases will be divided into treatment group（Sanjin tablets+ levofloxacin simulants），control group 1（Sanjin tablets simulants +levofloxacin）and control group 2（Sanjin tablets+ levofloxacin）. Each group will be treated for 7 days and followed up for 2 times. The efficacy indicators of this study were mainly from three dimensions: syndrome, laboratory routine examination and bacteriology examination. The symptom scores and cytokine changes of each group before and after treatment were observed.
Many health economic researchers prefer that a treatments effect is measured in the quantity and quality of life (Qol) the treatment provides. This enables them to calculate effect in the generic Quality Adjusted Life-Years (QALYs). Patients' Qol can be estimates by having patients' answer the EQ-5D-3L questionnaire. However, when performing a post hoc health economic evaluation, data is often incomplete. Often there is no information available regarding the patients' Qol and some health economic researchers therefore resort to various conversions of other measurements of effect to Qol. Such conversions thereby enable them to calculate effect in QALYs even though they had incomplete information. However, no method has been developed for converting eg. VAS pain scores to Qol and the methods currently used are arbitrary. With this study the investigators wish to develop such a method and in the process evaluate our own arbitrary Qol conversion from a prior study by asking the same type of patients. The study is an observational study with no intervention.
The invention discloses a biological preparation for resisting against replication and infection of a foot-and-mouth disease virus and a preparation method as well as application thereof. Active parts of the biological preparation are siRNA-VP1 and siRNA-2B; a nucleotide sequence of a sense strand of a transcription template of the siRNA-VP1 is shown as SEQ ID NO. 1; and a nucleotide sequence of a sense strand of a transcription template of the siRNA-2B is shown as SEQ ID NO. 3. In the invention, by connecting the transcription template of the siRNA-VP1 and the transcription template of the siRNA-2B with U6 promoter, human replicated defect 5 type adenovirus plasmid carrier pAdeno-X is cloned to obtain plasmids which can be transcribed and connected in series respectively; and next, cell packaging is performed through packaging to obtain recombinant adenovirus Adeno-2B-VP1. Experiments prove that the prevention and control effect of the recombinant adenovirus Adeno-2B-VP1 is superior to the effect obtained by independently applying the recombinant adenovirus siRNA-2B and the recombinant adenovirus Adeno-2B-VP1 or applying the recombinant adenovirus siRNA-2B and the recombinant adenovirus Adeno-2B-VP1 in a combined way. The biological preparation can be used for suppressing replication of the foot-and-mouth disease virus and resisting against the infection of the foot-and-mouth disease.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of NEUPOGEN or of other filgrastim products.

While available data suggest that a small proportion of patients developed binding antibodies to filgrastim, the nature and specificity of these antibodies has not been adequately studied. In clinical studies using NEUPOGEN, the incidence of antibodies binding to filgrastim was 3% (11/333). In these 11 patients, no evidence of a neutralizing response was observed using a cell based bioassay. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of NEUPOGEN is unknown.

Cytopenias resulting from an antibody response to exogenous growth factors have been reported on rare occasions in patients treated with other recombinant growth factors.
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare yet profoundly debilitating condition associated with high global case fatality and morbidity rates. The key determinants of functional outcome include early brain injury, rebleeding of the ruptured aneurysm and delayed cerebral ischaemia. The only effective way to reduce the risk of rebleeding is to secure the ruptured aneurysm quickly. Prompt diagnosis, transfer to specialized centers, and meticulous management in the intensive care unit (ICU) significantly improved the prognosis of aSAH. Recently, multimodality monitoring with specific interventions to correct pathophysiological imbalances has been proposed. Vigilance extends beyond intracranial concerns to encompass systemic respiratory and haemodynamic monitoring, as derangements in these systems can precipitate secondary brain damage. Challenges persist in treating aSAH patients, exacerbated by a paucity of robust clinical evidence, with many interventions showing no benefit when tested in rigorous clinical trials. Given the growing body of literature in this field and the issuance of contemporary guidelines, our objective is to furnish an updated review of essential principles of ICU management for this patient population. Our review will discuss the epidemiology, initial stabilization, treatment strategies, long-term prognostic factors, the identification and management of post-aSAH complications. We aim to offer practical clinical guidance to intensivists, grounded in current evidence and expert clinical experience, while adhering to a concise format.
The invention discloses an environment-friendly nuisance-free pesticide which is prepared from the raw materials of, by weight: 2.3-5.4 parts of dinitroaniline, 6.5-8.7 parts of geranium oil, 1.2-3.5 parts of a solvents, 1.1-3.4 parts of a surfactant, 2.3-3.7 parts of achnatherum inebrians, 1.8-3.4 parts of girald pteroxygonum root, 0.8-1.7 parts of wild tobacco, and 11.5-13.5 parts of water. The pesticide provided by the invention has the advantage of high efficacy. Compared with single ivermectin or a botanical pesticide, the insecticidal activity of the pesticide is substantially enhanced and is stable. The insecticidal spectrum is broad. The pesticide has controlling effects against aquatic animal body surface parasite. The pesticide has the advantages of mild potency and uniform dispersion, low irritation to aquatic animals, low cost, and small pollution to the environment. The pesticide is an environment-friendly nuisance-free pesticide.
The prevalence of malnutrition on admission to hospital varies between 15-60%. Knowing the extent of the problem and identifying at-risk patients should be a priority task since malnutrition is associated with increased hospital-related complications; longer length of stay, increased costs related to treatment and higher mortality. Post discharge, malnourished patients have also been linked to more frequent re-admissions, higher morbidity and mortality. Various screening tools are available, including the Nutrition Risk Screening-2002 recommended by European Society for Clinical Nutrition and Metabolism as the preferred screening tool for malnutrition in hospitals in Europe. ASPEN recommends a more comprehensive evaluation and diagnosis procedure. In South Africa, and the rest of Africa, nutritional screening is not routinely done and the investigators do not have any reliable national statistics indicating the extent of the problem. The aim of this study is to determine the prevalence of malnutrition on admission to hospital and to identify the impact thereof on relevant outcomes. Two different internationally recognised tools will be used and validated for the African context. In this multi-country, multi-centre descriptive cross-sectional study 3 hospitals in South Africa, 1 in Ghana and 2 in Kenya will be included. Adult patients (n=400 per hospital) will be screened on admission and at discharge and relevant outcomes (in-hospital and 3-month post-discharge) will be charted. A 50% sub-sample will be used to validate the 2 instruments.
PCT No. PCT/AU90/00039 Sec. 371 Date Aug. 1, 1991 Sec. 102(e) Date Aug. 1, 1991 PCT Filed Feb. 5, 1990 PCT Pub. No. WO90/08834 PCT Pub. Date Aug. 9, 1990.The present invention provides monoclonal antibodies directed against specific domains of fibronectin and vitronectin. These monoclonals may be used in the production of the biomaterial and devices for use in in vitro cell culture. The present invention also provides an efficient method for extracting vitronectin from bovine serum or plasma using monoclonal antibodies and methods for analyzing biological samples for the presence of adhesive glycoproteins or fragments thereof.
Patients that present to Dayton Children's Hospital with a head CT order for suspected TBI will be approached for enrollment. An alert will notify study personnel as CT scans are ordered. The goal is to obtain NIRS data within four-hours before or after the CT scan. Informed consent will be obtained according to institutional protocols. NIRS data will be obtained using Infrascanner model 2000 (Infrascanner Inc.). Eight data points will be collected for each subject in standard fashion from right to left frontal, temporal, parietal, and occipital locations. Study personnel will be trained by the manufacturer and will be blinded to the results of the CT scan. Data stored on the Infrascanner will be subsequently transferred to a password-protected database for storage and analysis. For each participant scanned with the Infrascanner 2000, they will be de-identified with a subject number, with patient demographics, mechanism of injury, GCS presentation, time of CT scan, and time of NIRS recorded. CT scan results comprise presence of epidural hematoma and/or subdural hematoma and its maximal thickness if present; presence of intraparenchymal hematoma; presence of skull fracture; and any other traumatic injuries contained in the CT scan report. The length of time required to acquire NIRS data will also be recorded for quality improvement purposes.

The specific aims of this study are to better understand the epidemiology of traumatic brain injury (TBI) at Dayton Children's Hospital, to establish the operating characteristics of NIRS for suspected traumatic intracranial hemorrhage at Dayton Children's Hospital, and to study the implementation of a new diagnostic modality in a busy tertiary care emergency department.
PURPOSE: A Lespedeza bicolor extract is provided to ensure strong antibacterial activity against Helocobacter pylori and to prevent or treat various gastrointestinal mucosa infectious diseases. CONSTITUTION: A Lespedeza bicolor extract has an antibacterial activity. The antibacterial activity is an activity against Helicobacter pylori. The Lespedeza bicolor extract is isolated using 40-60% ethanol as a solvent. A health food for preventing gastrointestinal mucosa infectious diseases by Helicobacter pylori contains Lespedeza bicolor extract as an active ingredient. A pharmaceutical composition for preventing and treating gastrointestinal mucosa infectious diseases by Helicobacter pylori contains Lespedeza bicolor extract as an active ingredient.
YUSIMRY (adalimumab-aqvh) is supplied as a preservative-free, sterile, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous administration. The following packaging configurations are available:

  * YUSIMRY Pen Carton - 40 mg/0.8 mL



YUSIMRY is supplied in a carton containing two dose trays. Each dose tray consists of a single-dose pen, containing a 1 mL prefilled glass syringe with a fixed ½ inch needle, providing 40 mg/0.8 mL of YUSIMRY. The needle cover is not manufactured from natural rubber latex. The NDC number is 71288-815-81.

  * Prefilled Syringe Carton - 40 mg/0.8 mL



YUSIMRY is supplied in a carton containing two dose trays. Each dose tray consists of a single-dose, 1 mL prefilled glass syringe with a fixed ½ inch needle, providing 40 mg/0.8 mL of YUSIMRY. The needle cover is not manufactured from natural rubber latex. The NDC number is 71288-816-81.

Storage and Stability

Do not use beyond the expiration date on the container. YUSIMRY must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Do not use if frozen, even if it has been thawed.

Store in original carton until time of administration to protect from light.

If needed, for example when traveling, YUSIMRY may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 14 days, with protection from light. YUSIMRY should be discarded if not used within the 14-day period. Record the date when YUSIMRY is first removed from the refrigerator in the spaces provided on the carton and dose pack.

Do not store YUSIMRY in extreme heat or cold.